Home » Biotechnology » Cell and Gene Therapy Manufacturing Market

Cell and Gene Therapy Manufacturing Market By Type (Cell Therapy Manufacturing – Stem Cell Therapy, Non-Stem Cell Therapy; Gene Therapy Manufacturing); By Scale (Pre-commercial/R&D Scale Manufacturing, Commercial Scale Manufacturing); By Mode (Contract Manufacturing, In-house Manufacturing); By Work Flow (Cell Processing, Cell Banking, Process Development, Fill & Finish Operations, Analytical and Quality Testing, Raw Material Testing, Vector Production, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Cell and Gene Therapy Manufacturing Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-04-01
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Cell and Gene Therapy Manufacturing Market

Summary
Table Of Content
Request Sample

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Cell and Gene Therapy Manufacturing Market Size 2024	USD 19,305.00 Million
Cell and Gene Therapy Manufacturing Market, CAGR	28.80%
Cell and Gene Therapy Manufacturing Market Size 2032	USD 146,216.60 Million

Market Overview

The global Cell and Gene Therapy Manufacturing Market is projected to grow from USD 19,305.00 million in 2024 to an estimated USD 146,216.60 million by 2032, with a compound annual growth rate (CAGR) of 28.80% from 2025 to 2032. This robust growth reflects the increasing demand for advanced therapeutic solutions and innovative manufacturing processes in the biotechnology and pharmaceutical industries.

Several factors drive this market’s growth, including advancements in gene editing technologies, such as CRISPR, and increasing investment in personalized medicine. The rising prevalence of genetic disorders, cancer, and rare diseases, combined with the growing acceptance of gene therapies, contributes to the market’s acceleration. Furthermore, the development of automated manufacturing processes, improvements in supply chain infrastructure, and the surge in strategic collaborations among pharmaceutical companies and research institutions are critical trends enhancing market growth.

Geographically, North America holds the largest market share, driven by the presence of leading biotech companies and robust healthcare infrastructure. However, regions such as Europe and Asia Pacific are expected to witness substantial growth due to increasing research activities and government initiatives to promote gene therapy. Key players in the global market include Novartis, Gilead Sciences, Bristol Myers Squibb, and Sartorius, who are actively involved in driving innovation and expanding production capacities in cell and gene therapy manufacturing.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights

The global Cell and Gene Therapy Manufacturing Market is expected to grow from USD 19,305.00 million in 2024 to USD 146,216.60 million by 2032, driven by advancements in gene therapies and manufacturing processes.
Technological advancements in gene editing, such as CRISPR, are enabling the development of more precise and effective therapies, accelerating market growth.
The increasing incidence of genetic disorders, cancer, and rare diseases is driving the demand for innovative gene therapies and personalized medicine solutions.
The high cost of manufacturing complex cell and gene therapies, along with the need for specialized facilities, is a key challenge in scaling production.
Stringent regulatory requirements and lengthy approval processes can delay the time-to-market for new therapies, limiting industry growth.
North America leads the market, supported by a strong biotechnology infrastructure, high demand for advanced therapies, and favorable regulatory frameworks.
Asia-Pacific is expected to witness substantial market growth due to increasing investments in research, government support for gene therapy, and growing healthcare access.

Market Drivers

Increased Investment and Funding in Biotech and Pharma Research

The global Cell and Gene Therapy Manufacturing Market is also being driven by the surge in investment and funding for biotechnology and pharmaceutical research. Venture capital funding, government grants, and corporate investments are being funneled into the development of gene therapies, which accelerates innovation in manufacturing technologies and processes. The rise in funding has allowed for greater exploration of novel therapeutic options and has provided the necessary financial resources for scaling up production processes. Additionally, partnerships between pharmaceutical companies and biotech firms are becoming increasingly common. These collaborations combine expertise in drug development with specialized knowledge in manufacturing, facilitating the development of therapies that can be produced at large scales. As more gene therapies receive regulatory approvals, including those from the FDA and EMA, further funding and investment are expected to flow into the market, which will drive the expansion of cell and gene therapy manufacturing capacities.

Regulatory Support and Growing Market Acceptance

Another critical factor driving growth in the global Cell and Gene Therapy Manufacturing Market is the increasing regulatory support and growing acceptance of gene therapies. In recent years, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have provided clearer frameworks for the approval of gene and cell therapies. This regulatory clarity helps to streamline the development process, encouraging more players to enter the market. Additionally, accelerated approval pathways, such as the FDA’s Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, have made it easier for companies to bring innovative therapies to market more quickly. These regulatory incentives are particularly important for the commercialization of gene therapies, as they provide the necessary pathways to facilitate market access. As gene therapies gain acceptance in clinical settings and patient populations, the demand for manufacturing capabilities continues to rise. Furthermore, the expanding number of commercially available gene therapies, including those for rare diseases and cancers, is fueling broader market acceptance, driving further investment and development in the sector.

Advancements in Gene Editing Technologies

One of the foremost drivers of growth in the global Cell and Gene Therapy Manufacturing Market is the rapid advancement of gene editing technologies. Techniques such as CRISPR-Cas9, TALENs, and ZFNs (Zinc Finger Nucleases) are revolutionizing the way genetic diseases are treated by enabling precise alterations to the DNA of cells. These innovations allow for the development of targeted gene therapies, making treatments more effective and personalized. For instance, CRISPR-Cas9 has successfully alleviated disease phenotypes in mouse models of type 1 diabetes, acute kidney injury, and muscular dystrophy. TALENs have been used to inactivate the LDL receptor gene in pigs, creating a model for familial hypercholesterolemia. ZFNs have been applied to genetically modify the gol pigment gene and the ntl gene in zebrafish embryos, demonstrating their ability to create heritable mutant alleles. As these technologies become more refined and accessible, the demand for advanced manufacturing solutions to produce gene-edited therapies is expected to grow exponentially, increasing the need for specialized facilities, skilled labor, and complex production methods.

Rising Prevalence of Genetic Disorders and Chronic Diseases

The increasing prevalence of genetic disorders, chronic diseases, and cancer is a major factor driving demand for cell and gene therapies. As healthcare providers and researchers look for new ways to address the root causes of diseases, gene therapies offer a promising avenue for long-term solutions. Genetic disorders such as cystic fibrosis, muscular dystrophy, and hemophilia, along with various types of cancer, have proven difficult to treat with traditional methods. For instance, Down syndrome affects babies born in the U.S. annually, with a similar impact observed in India. Sickle cell anaemia, cystic fibrosis, and Tay-Sachs disease are among the more common genetic disorders. Regarding chronic diseases, leukemias, brain and nervous system cancers, and lymphomas are the most prevalent malignant diseases in younger subjects. In the United States, high blood pressure, arthritis, respiratory diseases like emphysema, and high cholesterol are among the most common chronic conditions. This growing patient pool accelerates the demand for gene therapies, consequently driving the market for manufacturing capabilities and expansion.

Market Trends

Collaborations and Strategic Partnerships

Another notable trend is the rise of collaborations and strategic partnerships among biotechnology companies, pharmaceutical companies, contract manufacturing organizations (CMOs), and academic institutions. These partnerships are essential for advancing the development and manufacturing of cell and gene therapies, as they combine expertise in drug development with specialized manufacturing capabilities. Biotech firms are increasingly collaborating with larger pharmaceutical companies that have the financial resources and global reach to bring therapies to market. Additionally, partnerships with CMOs are becoming more common as companies seek to outsource the production of gene therapies to specialized facilities with expertise in the complexities of cell and gene therapy manufacturing. These collaborations allow for the pooling of resources, knowledge, and infrastructure, enabling companies to overcome the challenges associated with the high costs, specialized equipment, and regulatory hurdles involved in gene therapy manufacturing. Furthermore, partnerships with academic and research institutions help to accelerate the discovery and development of new gene therapies, providing a steady pipeline of innovative therapies that require cutting-edge manufacturing capabilities. The trend of collaborations and strategic alliances is expected to continue growing, as companies seek to enhance their manufacturing capabilities, improve operational efficiencies, and shorten the time to market for their therapies.

Advancements in Viral Vector Production Technologies

Viral vectors are essential tools for delivering gene therapies into patient cells, and advancements in viral vector production technologies represent a critical trend in the global Cell and Gene Therapy Manufacturing Market. Viral vectors, such as lentiviruses and adenoviruses, are commonly used to introduce genetic material into the target cells, and their production has traditionally been a bottleneck in the manufacturing process. As the demand for gene therapies increases, there has been a strong push toward improving the efficiency, scalability, and safety of viral vector production. Companies are investing in novel technologies such as suspension cell culture systems, which allow for higher yields of viral vectors, as well as improvements in vector engineering to enhance their safety and efficacy profiles. Additionally, there is a growing focus on developing viral vector platforms that can be used across a range of therapies, allowing for more efficient and cost-effective production processes. Innovations such as these are helping to overcome some of the key challenges faced by the industry, including high production costs, limited scalability, and long lead times. As advancements in viral vector production continue to emerge, they will further drive the growth and commercialization of gene therapies, facilitating their widespread adoption and paving the way for the next generation of treatments.

Shift Toward Scalable and Automated Manufacturing Processes

A significant trend in the global Cell and Gene Therapy Manufacturing Market is the increasing emphasis on scalable and automated manufacturing processes. Historically, the production of cell and gene therapies has been labor-intensive, highly specialized, and typically carried out in small batches due to the complexity of the therapies involved. However, as the demand for these therapies increases, manufacturers are focusing on developing scalable, automated production processes that can streamline the manufacturing workflow, reduce costs, and meet the growing demand for large-scale production. Automation not only enhances the efficiency and consistency of production but also minimizes the risk of human error, which is critical for the development of gene therapies where precision is paramount. Companies are investing heavily in developing and implementing technologies such as closed-loop systems, automated cell culture systems, and robotic handling of genetic materials to support the scalability of these complex therapies. For instance, the AUTOSTEM fully automated platform has been developed as a versatile solution for manufacturing and banking cell therapies. This GMP-ready platform allows for tissue collection, isolation, cell expansion, harvest, concentration, and cryopreservation of cell-based products. Its modularity and flexibility enable adaptation to various adherent and suspension cell types, expanding its applicability in cell and gene therapy manufacturing. These advances in automation are not only improving the economics of gene therapy production but are also making therapies more accessible by increasing production efficiency and reducing the time required to bring products to market.

Cell and Gene Therapy Integration with Personalized Medicine

The integration of cell and gene therapies with personalized medicine is another key trend shaping the global market. Personalized medicine refers to the customization of healthcare treatments based on individual genetic profiles, lifestyle, and environmental factors. Gene therapy is intrinsically tied to this concept, as it involves tailoring treatments to address the unique genetic mutations of individual patients. The ability to target specific genetic alterations within a patient’s genome allows for more effective and individualized therapies, reducing the risk of adverse reactions and improving the overall success of treatments. Personalized gene therapies are particularly relevant in the treatment of rare genetic disorders, cancer, and other conditions where traditional treatments may not be as effective. This trend is further supported by advances in gene sequencing, which have made it easier and more cost-effective to identify genetic variations in patients. The ability to design bespoke therapies that target the underlying cause of diseases is pushing the demand for cell and gene therapies, which, in turn, is prompting manufacturers to adapt their processes to meet the requirements of personalized treatments. Additionally, the FDA’s approval of personalized medications, including new molecular entities and cell/gene-based therapies, demonstrates the integration of cell and gene therapies with personalized medicine. These approvals highlight the growing trend of tailoring treatments to individual genetic profiles, offering more precise and effective therapeutic options for patients. As personalized medicine continues to gain traction, cell and gene therapy companies are aligning their strategies with this trend, driving market growth and innovation.

Market Challenges

Regulatory Hurdles and Supply Chain Complexity

Another key challenge in the cell and gene therapy manufacturing market is navigating the complex and evolving regulatory landscape. Regulatory bodies such as the FDA and EMA have stringent requirements for the approval of gene therapies, which can be time-consuming and expensive for manufacturers to meet. The approval process involves rigorous clinical trials, extensive documentation, and the need for long-term monitoring of therapy outcomes. Additionally, the supply chain for gene therapy production is highly specialized and often fragmented, involving numerous stakeholders, including research institutions, biotech firms, contract manufacturing organizations, and regulatory bodies. Managing the logistics and ensuring the consistency of raw materials, such as viral vectors and cell lines, across different regions can be a significant challenge. The complexity of these processes increases the risk of delays and supply chain disruptions, further escalating costs and hindering the timely delivery of therapies to patients. Effective management of both regulatory requirements and supply chain logistics is critical to ensuring the success of gene therapies in the market.

High Production Costs and Complex Manufacturing Processes in Cell and Gene Therapy

One of the primary challenges facing the global Cell and Gene Therapy Manufacturing Market is the high cost associated with producing these therapies. The manufacturing process is highly complex, requiring advanced technologies, specialized facilities, and skilled labor. For instance, the complexity and high cost are exemplified by the need for specialized facilities and skilled labor to handle custom, small-batch runs, particularly for personalized treatments like autologous cell therapies. These often involve viral vectors for gene delivery, introducing additional complexity due to stability and performance variability.The production often involves custom, small-batch runs, particularly for personalized treatments, which significantly increases costs. The process requires genetic material manipulation and specialized cell cultures, necessitating rigorous quality control measures to ensure safety and efficacy. This level of precision and customization significantly increases production costs, making these therapies expensive and limiting their scalability and accessibility, especially in regions with limited healthcare resources.As demand grows, manufacturers must invest in new technologies, automation, and scalable systems to meet increasing production needs while trying to lower overall costs. This challenge is compounded by the need to maintain regulatory compliance, adding another layer of complexity and cost. Despite the potential for significant clinical benefits, the high cost of production remains a barrier to broader adoption and accessibility, particularly in emerging markets.

Market Opportunities

Expanding Applications in Rare and Genetic Diseases

One of the most significant opportunities in the global Cell and Gene Therapy Manufacturing Market lies in the expanding applications of these therapies for rare and genetic diseases. Gene therapies have shown immense promise in treating disorders that were previously considered untreatable, such as rare genetic conditions and inherited diseases. As the global understanding of genetics advances, the identification and development of therapies for these rare conditions present a substantial market opportunity. With more orphan drug designations and regulatory incentives being introduced by agencies like the FDA and EMA, companies can accelerate the development of these targeted therapies. This creates a pathway for manufacturers to cater to a growing patient population that requires highly specialized, personalized treatment options. Additionally, advancements in gene-editing technologies and precision medicine enable manufacturers to produce therapies tailored to the genetic makeup of individual patients, further expanding the market potential.

Technological Innovations in Manufacturing and Automation

The second major opportunity for the global Cell and Gene Therapy Manufacturing Market is the technological advancements in manufacturing processes and automation. The growing demand for scalable production solutions creates opportunities for manufacturers to adopt innovative technologies that increase efficiency and reduce costs. Automation in the production of gene therapies is critical to improving consistency, reducing human error, and scaling production to meet the rising demand. Additionally, innovations in closed-loop systems, robotic cell handling, and the development of cost-effective viral vector production platforms are streamlining manufacturing operations. These technological advancements not only enable companies to produce gene therapies at a larger scale but also improve the overall accessibility and affordability of these therapies, opening up new market opportunities across the globe.

Market Segmentation Analysis

By Type

Cell Therapy Manufacturing is further divided into stem cell therapy and non-stem cell therapy. Stem cell therapy is one of the most widely recognized applications, offering potential treatments for a variety of conditions such as blood cancers, autoimmune diseases, and neurodegenerative disorders. Non-stem cell therapies include approaches such as T-cell therapies and CAR-T (Chimeric Antigen Receptor T-cell) therapies, which are increasingly utilized in cancer treatments.Gene Therapy Manufacturing involves the development and production of therapies that target genetic disorders by modifying or repairing genes. With advancements in gene editing technologies, such as CRISPR and TALEN, this segment is experiencing rapid growth, especially in the treatment of rare and inherited genetic diseases, as well as cancers.

By Scale

Pre-commercial/R&D Scale Manufacturing: This segment involves small-scale production aimed at research and development, clinical trials, and regulatory submissions. It requires highly specialized facilities and processes to meet strict regulatory standards. As these therapies progress through clinical phases, this scale serves as the foundation for further development.Commercial scale manufacturing refers to large-scale production after regulatory approval. This scale is essential for meeting the growing demand for approved gene and cell therapies. It requires significant investments in infrastructure, automation, and quality control to ensure consistent production at scale.

Segments

Based on Type

Cell therapy manufacturing
Stem cell therapy
Non stem cell therapy
Gene therapy manufacturing

Based on Scale

Pre-commercial/R&D scale manufacturing
Commercial scale manufacturing

Based on Mode

Contract manufacturing
In-house manufacturing

Based on Work Flow

Cell processing
Cell banking
Process development
Fill & finish operations
Analytical and quality testing
Raw material testing
Vector production
Others

Based on Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis

North America (45%)

North America holds the largest share of the global Cell and Gene Therapy Manufacturing Market, driven by significant investments in research and development, a strong biotechnology infrastructure, and favorable regulatory environments. The United States, in particular, plays a pivotal role due to the presence of leading pharmaceutical and biotechnology companies, such as Gilead Sciences, Novartis, and Vertex Pharmaceuticals, as well as well-established academic and research institutions. The FDA’s accelerated approval processes, including the Orphan Drug Designation and RMAT (Regenerative Medicine Advanced Therapy) designation, have facilitated faster commercialization of cell and gene therapies. Additionally, the rising prevalence of genetic disorders and cancer in the region has increased demand for advanced therapeutic solutions, further fueling market growth. The region’s strong healthcare infrastructure and increasing adoption of personalized medicine are expected to maintain North America’s dominant position in the market.

Europe (30%)

Europe is the second-largest market for cell and gene therapy manufacturing, with countries such as Germany, the UK, and France leading the market. The European Medicines Agency (EMA) provides a favorable regulatory framework, helping companies in Europe expedite the development and approval of cell and gene therapies. Furthermore, the European Union’s support for biotech innovation, coupled with significant investments in healthcare research, has contributed to the region’s growth. The market is also benefiting from the increasing number of strategic partnerships between biotechnology firms and contract manufacturing organizations (CMOs). As the demand for innovative treatments rises, Europe is becoming a key hub for the development and production of gene therapies, especially in the context of personalized medicine.

Key players

Hoffmann-La Roche Ltd.
Catalent Inc.
Samsung Biologics
Boehringer Ingelheim
Miltenyi Biotec
Merck KGaA

Competitive Analysis

The global Cell and Gene Therapy Manufacturing Market is highly competitive, with leading players such as F. Hoffmann-La Roche Ltd., Catalent Inc., and Samsung Biologics shaping the industry landscape. These companies leverage advanced manufacturing technologies and strong R&D capabilities to stay at the forefront of market development. F. Hoffmann-La Roche Ltd. is renowned for its extensive product portfolio and strategic business alliances, enabling it to maintain a dominant market position. Catalent Inc. stands out with its focus on providing end-to-end solutions for gene therapy, from development to commercial-scale manufacturing. Samsung Biologics offers cutting-edge biologics manufacturing services and has expanded its capabilities to include gene therapy production. Boehringer Ingelheim, Miltenyi Biotec, and Merck KGaA are also key players, each focusing on specialized areas such as viral vector production, gene editing, and cell therapy solutions. These companies’ robust strategies and innovative solutions are critical to maintaining their competitive edge in a rapidly evolving market.

Recent Developments

In March 2023, Catalent Inc. expanded its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors, including an in-house clonal HEK293 cell line and off-the-shelf plasmids to support a robust supply chain for gene therapies.
In September 2024, Samsung Biologics launched new innovative development platforms – S-AfuCHO and S-OptiCharge – at BioProcess International 2024. These platforms aim to address evolving industry trends and enable high-quality development for cell and gene therapies.

Market Concentration and Characteristics

The global Cell and Gene Therapy Manufacturing Market exhibits moderate to high market concentration, with a few key players dominating the landscape. Leading companies such as F. Hoffmann-La Roche Ltd., Catalent Inc., and Samsung Biologics control significant market share due to their extensive resources, advanced manufacturing technologies, and established expertise in the development of gene and cell therapies. However, the market also sees the emergence of smaller, specialized firms focusing on niche areas like viral vector production and personalized medicine. The market is characterized by a rapidly evolving competitive environment, driven by technological advancements, stringent regulatory requirements, and growing demand for innovative therapies. Strategic partnerships, collaborations, and acquisitions are common as companies seek to enhance their manufacturing capabilities and broaden their service offerings, further shaping the market’s concentration and competitive dynamics.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Type, Scale, Mode, Work Flow and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market is expected to witness a surge in investment in advanced manufacturing technologies, including automation and AI-driven systems, to improve scalability and reduce production costs.
As personalized medicine continues to gain traction, the demand for tailored cell and gene therapies will drive the market, requiring manufacturers to develop customized production processes.
The growing need for gene therapies will increase the demand for viral vectors, prompting manufacturers to focus on enhancing viral vector production techniques to meet clinical and commercial requirements.
Regulatory bodies worldwide are likely to streamline approval processes for cell and gene therapies, providing more clarity and faster pathways for market entry, boosting industry growth.
With continued advancements in gene editing technologies such as CRISPR, the market will expand as these tools make gene therapies more precise and effective for a broader range of conditions.
The increasing prevalence of rare genetic diseases will drive the demand for gene therapies, prompting manufacturers to scale production and enhance their therapeutic offerings for orphan diseases.
Partnerships between biotech firms, pharmaceutical companies, and contract manufacturers will intensify, helping companies leverage complementary expertise in research, development, and manufacturing.
Manufacturers will prioritize developing scalable, cost-efficient solutions to meet the growing global demand for gene and cell therapies while ensuring consistent quality and regulatory compliance.
As emerging markets, particularly in Asia-Pacific, show increased adoption of advanced therapeutic solutions, companies will focus on establishing local manufacturing hubs to meet regional demand.
The demand for commercial-scale production will drive companies to expand their facilities and invest in state-of-the-art technologies, enabling them to meet the global market’s growing therapeutic needs.

CHAPTER NO. 1 : INTRODUCTION 34
1.1.1. Report Description 34
Purpose of the Report 34
USP & Key Offerings 34
1.1.2. Key Benefits for Stakeholders 34
1.1.3. Target Audience 35
1.1.4. Report Scope 35
1.1.5. Regional Scope 36
CHAPTER NO. 2 : EXECUTIVE SUMMARY 37
2.1. Cell and Gene Therapy Manufacturing Market Snapshot 37
2.1.1. Global Cell and Gene Therapy Manufacturing Market, 2018 – 2032 (Number of Doses) (USD Million) 39
2.2. Insights from Primary Respondents 40
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 41
3.1. Russia-Ukraine and Israel-Palestine War Impacts 41
CHAPTER NO. 4 : CELL AND GENE THERAPY MANUFACTURING MARKET – INDUSTRY ANALYSIS 42
4.1. Introduction 42
4.2. Market Drivers 43
4.2.1. Growing Pipeline of Cell and Gene Therapy 43
4.2.2. Increase In Investment by Government and Private Players 44
4.3. Market Restraints 45
4.3.1. Technological Challenges Associated with Manufacturing 45
4.4. Market Opportunities 46
4.4.1. Market Opportunity Analysis 46
4.5. Porter’s Five Forces Analysis 47
CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 48
5.1. Company Market Share Analysis – 2023 48
5.1.1. Global Cell and Gene Therapy Manufacturing Market: Company Market Share, by Volume, 2023 48
5.1.2. Global Cell and Gene Therapy Manufacturing Market: Company Market Share, by Revenue, 2023 49
5.1.3. Global Cell and Gene Therapy Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 49
5.1.4. Global Cell and Gene Therapy Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 50
5.2. Global Cell and Gene Therapy Manufacturing Market Company Volume Market Share, 2023 51
5.3. Global Cell and Gene Therapy Manufacturing Market Company Revenue Market Share, 2023 52
5.4. Company Assessment Metrics, 2023 53
5.4.1. Stars 53
5.4.2. Emerging Leaders 53
5.4.3. Pervasive Players 53
5.4.4. Participants 53
5.5. Start-ups /SMEs Assessment Metrics, 2023 53
5.5.1. Progressive Companies 53
5.5.2. Responsive Companies 53
5.5.3. Dynamic Companies 53
5.5.4. Starting Blocks 53
5.6. Strategic Developments 54
5.6.1. Acquisitions & Mergers 54
New Product Launch 54
Regional Expansion 54
5.7. Key Players Product Matrix 55
CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 56
6.1. PESTEL 56
6.1.1. Political Factors 56
6.1.2. Economic Factors 56
6.1.3. Social Factors 56
6.1.4. Technological Factors 56
6.1.5. Environmental Factors 56
6.1.6. Legal Factors 56
6.2. Adjacent Market Analysis 56
CHAPTER NO. 7 : CELL AND GENE THERAPY MANUFACTURING MARKET – BY TYPE SEGMENT ANALYSIS 57
7.1. Cell and Gene Therapy Manufacturing Market Overview, by Type Segment 57
7.1.1. Cell and Gene Therapy Manufacturing Market Volume Share, By Type, 2023 & 2032 58
7.1.2. Cell and Gene Therapy Manufacturing Market Revenue Share, By Type, 2023 & 2032 58
7.1.3. Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, By Type 59
7.1.4. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 59
7.1.5. Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 60
7.2. Cell therapy manufacturing 61
7.2.1. Global Cell therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 62
7.2.2. Global Cell therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 62
7.2.3. Stem cell therapy 63
7.2.3.1. Global Stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 64
7.2.3.2. Global Stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 65
7.2.4. Non stem cell therapy 66
7.2.4.1. Global Non stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 67
7.2.4.2. Global Non stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 68
7.3. Gene therapy manufacturing 69
7.3.1. Global Gene therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 70
7.3.2. Global Gene therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 70
CHAPTER NO. 8 : CELL AND GENE THERAPY MANUFACTURING MARKET – BY SCALE SEGMENT ANALYSIS 71
8.1. Cell and Gene Therapy Manufacturing Market Overview, by Scale Segment 71
8.1.1. Cell and Gene Therapy Manufacturing Market Volume Share, By Scale, 2023 & 2032 72
8.1.2. Cell and Gene Therapy Manufacturing Market Revenue Share, By Scale, 2023 & 2032 72
8.1.3. Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, By Scale 73
8.1.4. Incremental Revenue Growth Opportunity, by Scale, 2024 – 2032 73
8.1.5. Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018, 2023, 2027 & 2032 74
8.2. Pre-commercial/R&D scale manufacturing 75
8.2.1. Global Pre-commercial/R&D scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 76
8.2.2. Global Pre-commercial/R&D scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 77
8.3. Commercial scale manufacturing 78
8.3.1. Global Commercial scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 79
8.3.2. Global Commercial scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 79
CHAPTER NO. 9 : CELL AND GENE THERAPY MANUFACTURING MARKET – BY MODE SEGMENT ANALYSIS 80
9.1. Cell and Gene Therapy Manufacturing Market Overview, by Mode Segment 80
9.1.1. Cell and Gene Therapy Manufacturing Market Volume Share, By Mode, 2023 & 2032 81
9.1.2. Cell and Gene Therapy Manufacturing Market Revenue Share, By Mode, 2023 & 2032 81
9.1.3. Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, By Mode 82
9.1.4. Incremental Revenue Growth Opportunity, by Mode, 2024 – 2032 82
9.1.5. Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018, 2023, 2027 & 2032 83
9.2. Contract manufacturing 84
9.2.1. Global Contract manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 85
9.2.2. Global Contract manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 85
9.3. In-house manufacturing 86
9.3.1. Global In-house manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 87
9.3.2. Global In-house manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 87
CHAPTER NO. 10 : CELL AND GENE THERAPY MANUFACTURING MARKET – BY WORKFLOW SEGMENT ANALYSIS 88
10.1. Cell and Gene Therapy Manufacturing Market Overview, by Workflow Segment 88
10.1.1. Cell and Gene Therapy Manufacturing Market Volume Share, By Distribution Channel, 2023 & 2032 89
10.1.2. Cell and Gene Therapy Manufacturing Market Revenue Share, By Distribution Channel, 2023 & 2032 89
10.1.3. Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, By Distribution Channel 90
10.1.4. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 90
10.1.5. Cell and Gene Therapy Manufacturing Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 91
10.2. Cell processing 92
10.2.1. Global Cell processing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 93
10.2.2. Global Cell processing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 94
10.3. Cell banking 95
10.3.1. Global Cell banking Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 96
10.3.2. Global Cell banking Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 97
10.4. Process development 98
10.5. Global Process development Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 99
10.6. Global Process development Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 100
10.7. Fill & finish operations 101
10.7.1. Global Fill & finish operations Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 102
10.7.2. Global Fill & finish operations Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 103
10.8. Analytical and quality testing 104
10.8.1. Global Analytical and quality testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 105
10.8.2. Global Analytical and quality testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 106
10.9. Raw material testing 107
10.9.1. Global Raw material testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 108
10.9.2. Global Raw material testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 109
10.10. Vector production 110
10.10.1. Global Vector production Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 111
10.10.2. Global Vector production Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 112
10.11. Others 113
10.11.1. Global Others Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 114
10.11.2. Global Others Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 115
CHAPTER NO. 11 : CELL AND GENE THERAPY MANUFACTURING MARKET – REGIONAL ANALYSIS 116
11.1. Cell and Gene Therapy Manufacturing Market Overview, by Regional Segments 116
11.2. Region 117
11.2.1. Global Cell and Gene Therapy Manufacturing Market Volume Share, By Region, 2023 & 2032 117
11.2.2. Global Cell and Gene Therapy Manufacturing Market Revenue Share, By Region, 2023 & 2032 117
11.2.3. Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, By Region 118
11.2.4. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 118
11.2.5. Cell and Gene Therapy Manufacturing Market Revenue, By Region, 2018, 2023, 2027 & 2032 119
11.2.6. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 120
11.2.7. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 120
11.3. Type 121
11.3.1. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Type, 2018 – 2023 (Number of Doses) (USD Million) 121
11.3.2. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Type, 2024 – 2032 (Number of Doses) (USD Million) 122
11.4. Scale 123
11.4.1. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Scale, 2018 – 2023 (Number of Doses) (USD Million) 123
11.4.2. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Scale, 2024 – 2032 (Number of Doses) (USD Million) 124
11.5. Mode 125
11.5.1. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Mode, 2018 – 2023 (Number of Doses) (USD Million) 125
11.5.2. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Mode, 2024 – 2032 (Number of Doses) (USD Million) 126
11.6. Distribution Channel 127
11.6.1. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Distribution Channel, 2018 – 2023 (Number of Doses) (USD Million) 127
11.6.2. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Distribution Channel, 2024 – 2032 (Number of Doses) (USD Million) 128
CHAPTER NO. 12 : CELL AND GENE THERAPY MANUFACTURING MARKET – NORTH AMERICA 129
12.1. North America 129
12.1.1. Key Highlights 129
12.1.2. North America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 130
12.1.3. North America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 131
12.1.4. North America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 132
12.1.5. North America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 133
12.1.6. North America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 134
12.1.7. North America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 135
12.1.8. North America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 136
12.1.9. North America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 137
12.1.10. North America Cell and Gene Therapy Manufacturing Market Volume, By Distribution Channel, 2018 – 2023 (Number of Doses) 138
12.1.11. North America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 139
12.2. U.S. 140
12.3. Canada 140
12.4. Mexico 140
CHAPTER NO. 13 : CELL AND GENE THERAPY MANUFACTURING MARKET – EUROPE 141
13.1. Europe 141
13.1.1. Key Highlights 141
13.1.2. Europe Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 142
13.1.3. Europe Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 144
13.1.4. Europe Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 145
13.1.5. Europe Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 146
13.1.6. Europe Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 147
13.1.7. Europe Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 148
13.1.8. Europe Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 149
13.1.9. Europe Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 150
13.1.10. Europe Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 151
13.1.11. Europe Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 152
13.2. UK 153
13.3. France 153
13.4. Germany 153
13.5. Italy 153
13.6. Spain 153
13.7. Russia 153
13.8. Belgium 153
13.9. Netherland 153
13.10. Austria 153
13.11. Sweden 153
13.12. Poland 153
13.13. Denmark 153
13.14. Switzerland 153
13.15. Rest of Europe 153
CHAPTER NO. 14 : CELL AND GENE THERAPY MANUFACTURING MARKET – ASIA PACIFIC 154
14.1. Asia Pacific 154
14.1.1. Key Highlights 154
14.1.2. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 155
14.1.3. Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 156
14.1.4. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 157
14.1.5. Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 158
14.1.6. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 159
14.1.7. Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 160
14.1.8. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 161
14.1.9. Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 162
14.1.10. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 163
14.1.11. Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 164
14.2. China 165
14.3. Japan 165
14.4. South Korea 165
14.5. India 165
14.6. Australia 165
14.7. Thailand 165
14.8. Indonesia 165
14.9. Vietnam 165
14.10. Malaysia 165
14.11. Philippines 165
14.12. Taiwan 165
14.13. Rest of Asia Pacific 165
CHAPTER NO. 15 : CELL AND GENE THERAPY MANUFACTURING MARKET – LATIN AMERICA 166
15.1. Latin America 166
15.1.1. Key Highlights 166
15.1.2. Latin America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 167
15.1.3. Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 168
15.1.4. Latin America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 169
15.1.5. Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 170
15.1.6. Latin America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 171
15.1.7. Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 172
15.1.8. Latin America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 173
15.1.9. Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 174
15.1.10. Latin America Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 175
15.1.11. Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 176
15.2. Brazil 177
15.3. Argentina 177
15.4. Peru 177
15.5. Chile 177
15.6. Colombia 177
15.7. Rest of Latin America 177
CHAPTER NO. 16 : CELL AND GENE THERAPY MANUFACTURING MARKET – MIDDLE EAST 178
16.1. Middle East 178
16.1.1. Key Highlights 178
16.1.2. Middle East Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 179
16.1.3. Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 180
16.1.4. Middle East Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 181
16.1.5. Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 182
16.1.6. Middle East Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 183
16.1.7. Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 184
16.1.8. Middle East Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 185
16.1.9. Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 186
16.1.10. Middle East Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 187
16.1.11. Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 188
16.2. UAE 189
16.3. KSA 189
16.4. Israel 189
16.5. Turkey 189
16.6. Iran 189
16.7. Rest of Middle East 189
CHAPTER NO. 17 : CELL AND GENE THERAPY MANUFACTURING MARKET – AFRICA 190
17.1. Africa 190
17.1.1. Key Highlights 190
17.1.2. Africa Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2032 (Number of Doses) 191
17.1.3. Africa Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 192
17.1.4. Africa Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 193
17.1.5. Africa Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 194
17.1.6. Africa Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 195
17.1.7. Africa Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 196
17.1.8. Africa Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 197
17.1.9. Africa Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 198
17.1.10. Africa Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 199
17.1.11. Africa Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 200
17.2. Egypt 201
17.3. Nigeria 201
17.4. Algeria 201
17.5. Morocco 201
17.6. Rest of Africa 201
CHAPTER NO. 18 : COMPANY PROFILES 202
18.1. F. Hoffmann-La Roche Ltd. 202
18.1.1. Company Overview 202
18.1.2. Product Portfolio 202
18.1.3. Swot Analysis 202
18.1.4. Business Strategy 202
18.1.5. Financial Overview 203
18.2. Catalent Inc 204
18.3. Samsung Biologics 204
18.4. Boehringer Ingelheim 204
18.5. Miltenyi Biotec 204
18.6. Merck KGaA 204
18.7. Company 7 204
18.8. Company 8 204
18.9. Company 9 204
18.10. Company 10 204
18.11. Company 11 204
18.12. Company 12 204
18.13. Company 13 204
18.14. Company 14 204

List of Figures
FIG NO. 1. Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 39
FIG NO. 2. Porter’s Five Forces Analysis for Global Cell and Gene Therapy Manufacturing Market 47
FIG NO. 3. Company Share Analysis, 2023 48
FIG NO. 4. Company Share Analysis, 2023 49
FIG NO. 5. Company Share Analysis, 2023 49
FIG NO. 6. Company Share Analysis, 2023 50
FIG NO. 7. Cell and Gene Therapy Manufacturing Market – Company Volume Market Share, 2023 51
FIG NO. 8. Cell and Gene Therapy Manufacturing Market – Company Revenue Market Share, 2023 52
FIG NO. 9. Cell and Gene Therapy Manufacturing Market Volume Share, By Type, 2023 & 2032 58
FIG NO. 10. Cell and Gene Therapy Manufacturing Market Revenue Share, By Type, 2023 & 2032 58
FIG NO. 11. Market Attractiveness Analysis, By Type 59
FIG NO. 12. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 59
FIG NO. 13. Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 60
FIG NO. 14. Global Cell and Gene Therapy Manufacturing Market for Cell therapy manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 61
FIG NO. 15. Global Cell and Gene Therapy Manufacturing Market for Stem cell therapy, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 63
FIG NO. 16. Global Cell and Gene Therapy Manufacturing Market for Non stem cell therapy, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 66
FIG NO. 17. Global Cell and Gene Therapy Manufacturing Market for Gene therapy manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 69
FIG NO. 18. Cell and Gene Therapy Manufacturing Market Volume Share, By Scale, 2023 & 2032 72
FIG NO. 19. Cell and Gene Therapy Manufacturing Market Revenue Share, By Scale, 2023 & 2032 72
FIG NO. 20. Market Attractiveness Analysis, By Scale 73
FIG NO. 21. Incremental Revenue Growth Opportunity by Scale, 2024 – 2032 73
FIG NO. 22. Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018, 2023, 2027 & 2032 74
FIG NO. 23. Global Cell and Gene Therapy Manufacturing Market for Pre-commercial/R&D scale manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 75
FIG NO. 24. Global Cell and Gene Therapy Manufacturing Market for Commercial scale manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 78
FIG NO. 25. Cell and Gene Therapy Manufacturing Market Volume Share, By Mode, 2023 & 2032 81
FIG NO. 26. Cell and Gene Therapy Manufacturing Market Revenue Share, By Mode, 2023 & 2032 81
FIG NO. 27. Market Attractiveness Analysis, By Mode 82
FIG NO. 28. Incremental Revenue Growth Opportunity by Mode, 2024 – 2032 82
FIG NO. 29. Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018, 2023, 2027 & 2032 83
FIG NO. 30. Global Cell and Gene Therapy Manufacturing Market for Contract manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 84
FIG NO. 31. Global Cell and Gene Therapy Manufacturing Market for In-house manufacturing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 86
FIG NO. 32. Cell and Gene Therapy Manufacturing Market Volume Share, By Distribution Channel, 2023 & 2032 89
FIG NO. 33. Cell and Gene Therapy Manufacturing Market Revenue Share, By Distribution Channel, 2023 & 2032 89
FIG NO. 34. Market Attractiveness Analysis, By Distribution Channel 90
FIG NO. 35. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 90
FIG NO. 36. Cell and Gene Therapy Manufacturing Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 91
FIG NO. 37. Global Cell and Gene Therapy Manufacturing Market for Cell processing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 92
FIG NO. 38. Global Cell and Gene Therapy Manufacturing Market for Cell banking, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 95
FIG NO. 39. Global Cell and Gene Therapy Manufacturing Market for Process development, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 98
FIG NO. 40. Global Cell and Gene Therapy Manufacturing Market for Fill & finish operations, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 101
FIG NO. 41. Global Cell and Gene Therapy Manufacturing Market for Analytical and quality testing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 104
FIG NO. 42. Global Cell and Gene Therapy Manufacturing Market for Raw material testing, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 107
FIG NO. 43. Global Cell and Gene Therapy Manufacturing Market for Vector production, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 110
FIG NO. 44. Global Cell and Gene Therapy Manufacturing Market for Others, Volume & Revenue (Number of Doses) (USD Million) 2018 – 2032 113
FIG NO. 45. Global Cell and Gene Therapy Manufacturing Market Volume Share, By Region, 2023 & 2032 117
FIG NO. 46. Global Cell and Gene Therapy Manufacturing Market Revenue Share, By Region, 2023 & 2032 117
FIG NO. 47. Market Attractiveness Analysis, By Region 118
FIG NO. 48. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 118
FIG NO. 49. Cell and Gene Therapy Manufacturing Market Revenue, By Region, 2018, 2023, 2027 & 2032 119
FIG NO. 50. North America Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 129
FIG NO. 51. Europe Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 141
FIG NO. 52. Asia Pacific Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 154
FIG NO. 53. Latin America Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 166
FIG NO. 54. Middle East Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 178
FIG NO. 55. Africa Cell and Gene Therapy Manufacturing Market Volume & Revenue, 2018 – 2032 (Number of Doses) (USD Million) 190

List of Tables
TABLE NO. 1. : Global Cell and Gene Therapy Manufacturing Market: Snapshot 37
TABLE NO. 2. : Drivers for the Cell and Gene Therapy Manufacturing Market: Impact Analysis 43
TABLE NO. 3. : Restraints for the Cell and Gene Therapy Manufacturing Market: Impact Analysis 45
TABLE NO. 4. : Global Cell therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 62
TABLE NO. 5. : Global Cell therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 62
TABLE NO. 6. : Global Stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 64
TABLE NO. 7. : Global Stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 65
TABLE NO. 8. : Global Non stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 67
TABLE NO. 9. : Global Non stem cell therapy Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 68
TABLE NO. 10. : Global Gene therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 70
TABLE NO. 11. : Global Gene therapy manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 70
TABLE NO. 12. : Global Pre-commercial/R&D scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 76
TABLE NO. 13. : Global Pre-commercial/R&D scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 77
TABLE NO. 14. : Global Commercial scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 79
TABLE NO. 15. : Global Commercial scale manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 79
TABLE NO. 16. : Global Contract manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 85
TABLE NO. 17. : Global Contract manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 85
TABLE NO. 18. : Global In-house manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 87
TABLE NO. 19. : Global In-house manufacturing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 87
TABLE NO. 20. : Global Cell processing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 93
TABLE NO. 21. : Global Cell processing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 94
TABLE NO. 22. : Global Cell banking Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 96
TABLE NO. 23. : Global Cell banking Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 97
TABLE NO. 24. : Global Process development Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 99
TABLE NO. 25. : Global Process development Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 100
TABLE NO. 26. : Global Fill & finish operations Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 102
TABLE NO. 27. : Global Fill & finish operations Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 103
TABLE NO. 28. : Global Analytical and quality testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 105
TABLE NO. 29. : Global Analytical and quality testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 106
TABLE NO. 30. : Global Raw material testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 108
TABLE NO. 31. : Global Raw material testing Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 109
TABLE NO. 32. : Global Vector production Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 111
TABLE NO. 33. : Global Vector production Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 112
TABLE NO. 34. : Global Others Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 114
TABLE NO. 35. : Global Others Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 115
TABLE NO. 36. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2018 – 2023 (Number of Doses) (USD Million) 120
TABLE NO. 37. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Region, 2024 – 2032 (Number of Doses) (USD Million) 120
TABLE NO. 38. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Type, 2018 – 2023 (Number of Doses) (USD Million) 121
TABLE NO. 39. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Type, 2024 – 2032 (Number of Doses) (USD Million) 122
TABLE NO. 40. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Scale, 2018 – 2023 (Number of Doses) (USD Million) 123
TABLE NO. 41. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Scale, 2024 – 2032 (Number of Doses) (USD Million) 124
TABLE NO. 42. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Mode, 2018 – 2023 (Number of Doses) (USD Million) 125
TABLE NO. 43. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Mode, 2024 – 2032 (Number of Doses) (USD Million) 126
TABLE NO. 44. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Distribution Channel, 2018 – 2023 (Number of Doses) (USD Million) 127
TABLE NO. 45. : Global Cell and Gene Therapy Manufacturing Market Volume & Revenue, By Distribution Channel, 2024 – 2032 (Number of Doses) (USD Million) 128
TABLE NO. 46. : North America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 130
TABLE NO. 47. : North America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 130
TABLE NO. 48. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 131
TABLE NO. 49. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 131
TABLE NO. 50. : North America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 132
TABLE NO. 51. : North America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 132
TABLE NO. 52. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 133
TABLE NO. 53. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 133
TABLE NO. 54. : North America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 134
TABLE NO. 55. : North America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 134
TABLE NO. 56. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 135
TABLE NO. 57. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 135
TABLE NO. 58. : North America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 136
TABLE NO. 59. : North America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 136
TABLE NO. 60. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 137
TABLE NO. 61. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 137
TABLE NO. 62. : North America Cell and Gene Therapy Manufacturing Market Volume, By Distribution Channel, 2018 – 2023 (Number of Doses) 138
TABLE NO. 63. : North America Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 138
TABLE NO. 64. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 139
TABLE NO. 65. : North America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 139
TABLE NO. 66. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 142
TABLE NO. 67. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 143
TABLE NO. 68. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 144
TABLE NO. 69. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 144
TABLE NO. 70. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 145
TABLE NO. 71. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 145
TABLE NO. 72. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 146
TABLE NO. 73. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 146
TABLE NO. 74. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 147
TABLE NO. 75. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 147
TABLE NO. 76. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 148
TABLE NO. 77. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 148
TABLE NO. 78. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 149
TABLE NO. 79. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 149
TABLE NO. 80. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 150
TABLE NO. 81. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 150
TABLE NO. 82. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 151
TABLE NO. 83. : Europe Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 151
TABLE NO. 84. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 152
TABLE NO. 85. : Europe Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 152
TABLE NO. 86. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 155
TABLE NO. 87. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 155
TABLE NO. 88. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 156
TABLE NO. 89. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 156
TABLE NO. 90. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 157
TABLE NO. 91. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 157
TABLE NO. 92. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 158
TABLE NO. 93. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 158
TABLE NO. 94. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 159
TABLE NO. 95. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 159
TABLE NO. 96. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 160
TABLE NO. 97. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 160
TABLE NO. 98. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 161
TABLE NO. 99. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 161
TABLE NO. 100. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 162
TABLE NO. 101. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 162
TABLE NO. 102. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 163
TABLE NO. 103. : Asia Pacific Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 163
TABLE NO. 104. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 164
TABLE NO. 105. : Asia Pacific Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 164
TABLE NO. 106. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 167
TABLE NO. 107. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 167
TABLE NO. 108. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 168
TABLE NO. 109. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 168
TABLE NO. 110. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 169
TABLE NO. 111. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 169
TABLE NO. 112. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 170
TABLE NO. 113. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 170
TABLE NO. 114. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 171
TABLE NO. 115. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 171
TABLE NO. 116. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 172
TABLE NO. 117. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 172
TABLE NO. 118. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 173
TABLE NO. 119. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 173
TABLE NO. 120. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 174
TABLE NO. 121. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 174
TABLE NO. 122. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 175
TABLE NO. 123. : Latin America Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 175
TABLE NO. 124. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 176
TABLE NO. 125. : Latin America Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 176
TABLE NO. 126. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 179
TABLE NO. 127. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 179
TABLE NO. 128. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 180
TABLE NO. 129. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 180
TABLE NO. 130. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 181
TABLE NO. 131. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 181
TABLE NO. 132. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 182
TABLE NO. 133. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 182
TABLE NO. 134. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 183
TABLE NO. 135. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 183
TABLE NO. 136. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 184
TABLE NO. 137. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 184
TABLE NO. 138. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 185
TABLE NO. 139. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 185
TABLE NO. 140. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 186
TABLE NO. 141. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 186
TABLE NO. 142. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 187
TABLE NO. 143. : Middle East Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 187
TABLE NO. 144. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 188
TABLE NO. 145. : Middle East Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 188
TABLE NO. 146. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Country, 2018 – 2023 (Number of Doses) 191
TABLE NO. 147. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Country, 2024 – 2032 (Number of Doses) 191
TABLE NO. 148. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 192
TABLE NO. 149. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 192
TABLE NO. 150. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Type, 2018 – 2023 (Number of Doses) 193
TABLE NO. 151. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Type, 2024 – 2032 (Number of Doses) 193
TABLE NO. 152. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 194
TABLE NO. 153. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 194
TABLE NO. 154. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2018 – 2023 (Number of Doses) 195
TABLE NO. 155. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Scale, 2024 – 2032 (Number of Doses) 195
TABLE NO. 156. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2018 – 2023 (USD Million) 196
TABLE NO. 157. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Scale, 2024 – 2032 (USD Million) 196
TABLE NO. 158. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2018 – 2023 (Number of Doses) 197
TABLE NO. 159. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Mode, 2024 – 2032 (Number of Doses) 197
TABLE NO. 160. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2018 – 2023 (USD Million) 198
TABLE NO. 161. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Mode, 2024 – 2032 (USD Million) 198
TABLE NO. 162. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2018 – 2023 (Number of Doses) 199
TABLE NO. 163. : Africa Cell and Gene Therapy Manufacturing Market Volume, By Workflow, 2024 – 2032 (Number of Doses) 199
TABLE NO. 164. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2018 – 2023 (USD Million) 200
TABLE NO. 165. : Africa Cell and Gene Therapy Manufacturing Market Revenue, By Workflow, 2024 – 2032 (USD Million) 200

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Frequently Asked Questions:

What is the market size of the global Cell and Gene Therapy Manufacturing Market in 2023 and 2032?

The market size is projected to be USD 19,305.00 million in 2024 and reach USD 146,216.60 million by 2032, with a compound annual growth rate (CAGR) of 28.80% from 2025 to 2032.

What factors are driving the growth of the Cell and Gene Therapy Manufacturing Market?

The growth is driven by advancements in gene editing technologies, increasing investment in personalized medicine, and the rising prevalence of genetic disorders and cancer.

Which regions dominate the global Cell and Gene Therapy Manufacturing Market?

North America holds the largest market share, followed by Europe and Asia Pacific, with the latter expected to witness significant growth due to rising research activities and government support for gene therapy.

What are the key trends in the Cell and Gene Therapy Manufacturing Market?

Key trends include the shift towards scalable and automated manufacturing, integration with personalized medicine, strategic collaborations, and advancements in viral vector production technologies.

Who are the leading players in the global Cell and Gene Therapy Manufacturing Market?

Leading players include Novartis, Gilead Sciences, Bristol Myers Squibb, and Sartorius, which are actively expanding production capacities and driving innovation in gene therapy manufacturing.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Thin Film Solar Cell Market

The Thin Film Solar Cell Market size was valued at USD 17649 million in 2024 and is anticipated to reach USD 37832.1 million by 2032, at a CAGR of 10% during the forecast period (2024-2032).

Stationary Fuel Cells Market

The stationary fuel cell market is projected to grow from USD 1,549 million in 2024 to USD 4,265.9 million by 2032, expanding at a CAGR of 13.5%.

Coin Cell Batteries Market

The Coin Cell Batteries market size was valued at USD 4,400.00 million in 2018, increased to USD 5,610.88 million in 2024, and is anticipated to reach USD 9,967.73 million by 2032, growing at a CAGR of 7.51% during the forecast period.

Hairy Cell Leukemia Market

The Hairy Cell Leukemia Market size was valued at USD 141.5 million in 2024 and is anticipated to reach USD 230.6 million by 2032, at a CAGR of 6.3% during the forecast period (2024-2032).

Blood Cell Factors Market

The Blood Cell Factors Market size was valued at USD 2,150 million in 2024 and is anticipated to reach USD 3,375 million by 2032, at a CAGR of 5.8 % during the forecast period (2024-2032).

Multi-Junction Solar Cell Market

The Multi-Junction Solar Cell market size was valued at USD 954.36 million in 2018, increased to USD 1,991.92 million in 2024, and is anticipated to reach USD 6,743.74 million by 2032, at a CAGR of 15.35% during the forecast period.

Cell Culture Protein Surface Coatings Market

The Global Cell Culture Protein Surface Coatings Market is projected to grow from USD 1,059.4 million in 2024 to an estimated USD 2,245.1 million by 2032, with a compound annual growth rate (CAGR) of 9.87% from 2025 to 2032.

Automated Cell Shakers Market

Automated Cell Shakers Market size was valued at USD 698 million in 2024 and is
anticipated to reach USD 1190.3 million by 2032, at a CAGR of 6.9% during the forecast
period (2024-2032).

Stem Cells Market

The Stem Cells Market size was valued at USD 1,144.3 million in 2018, increased to USD 2,235.6 million in 2024, and is anticipated to reach USD 5,380.3 million by 2032, at a CAGR of 11.66% during the forecast period.

Plasma Feed Market

The plasma feed market is projected to grow from USD 908.3 million in 2024 to USD 1,918.9 million by 2032, registering a CAGR of 9.8% during the forecast period.

Biofertilizers Market

The Biofertilizers Market size was valued at USD 2674.5 million in 2024 and is anticipated to reach USD 5136.7 million by 2032, at a CAGR of 8.5% during the forecast period.

Synthetic and Bio Thermosets Market

The Synthetic and Bio thermosets Market size was valued at USD 11,195 million in 2024 and is anticipated to reach USD 15,678.2 million by 2032, growing at a CAGR of 4.3% during the forecast period.

Isothermal Nucleic Acid Amplification Technology Market

The Isothermal nucleic acid amplification technology market is projected to grow from USD 623 million in 2024 to an estimated USD 1,259.7 million by 2032, with a compound annual growth rate (CAGR) of 9.2% from 2024 to 2032.

MEA Biologics and Biosimilars Market

The Middle East and Africa (MEA) Biologics and Biosimilars market size was valued at USD 457.69 million in 2018, increased to USD 649.05 million in 2024, and is anticipated to reach USD 1,023.42 million by 2032, at a CAGR of 5.45% during the forecast period.

Neuro Organoids Market

The Neuro Organoids market size was valued at USD 39.70 million in 2018, increased to USD 85.51 million in 2024, and is anticipated to reach USD 420.35 million by 2032, at a CAGR of 20.54% during the forecast period.

Lignin-Based Plastics Market

The Lignin-Based Plastics Market size was valued at USD 1,150.00 million in 2018 to USD 1,353.50 million in 2024 and is anticipated to reach USD 1,983.51 million by 2032, at a CAGR of 4.92% during the forecast period.

Olfactory Sensing ASIC Market

The Global Olfactory Sensing ASIC Market size was valued at USD 188.10 million in 2018 to USD 383.67 million in 2024 and is anticipated to reach USD 1,202.61 million by 2032, at a CAGR of 14.31% during the forecast period.

Bio-Integrated Sensor ASIC Market

The Global Bio-Integrated Sensor ASIC Market size was valued at USD 15,054.14 million in 2018 and is projected to reach USD 27,514.86 million by 2024. It is anticipated to grow to USD 66,163.22 million by 2032, at a CAGR of 10.80% during the forecast period.

Ocular Drug Delivery Technologies Market

The Ocular Drug Delivery Technologies market size was valued at USD 10,506.93 million in 2018, increased to USD 15,121.67 million in 2024, and is anticipated to reach USD 25,989.57 million by 2032, growing at a CAGR of 7.07% during the forecast period.

Molecular Weight Markers Market

The Molecular Weight Markers market size was valued at USD 387.3 million in 2018, grew to USD 841.4 million in 2024, and is anticipated to reach USD 2,259.8 million by 2032, at a CAGR of 13.19% during the forecast period.

Virus Safety Testing Services Market

The Virus Safety Testing Services Market size was valued at USD 657.4 million in 2024 and is anticipated to reach USD 2261.4 million by 2032, at a CAGR of 16.7 % during the forecast period (2024-2032).

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert